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Abstract 
 
Background: The QUOROM and PRISMA guidelines were created in an attempt to improve the 
standard of reporting systematic reviews. At present there are no studies in the dental literature 
that have assessed the compliance of papers with these two sets of guidelines. 
Aims: To determine whether the reports of systematic reviews in four dental specialities comply 
with the QUOROM and PRISMA statements, whether there has been an improvement in 
standard over time and whether Cochrane reviews differ from other reviews. 
Design: Retrospective observational study 
Method: A search of the Cochrane library identified 181 systematic reviews and meta-analyses 
for inclusion across four dental specialities (orthodontics, periodontics, preventive dentistry and 
endodontics). Each review was scored using a 63-item checklist developed from the QUOROM 
guidelines and a 63-item checklist developed from the PRISMA guidelines. 
Results: The mean QUOROM score for the whole sample was 70.86% (SD 11.36%, 95% CI 
69.20%, 70.86%) and the mean PRISMA score for the whole sample was 74.07% (SD 10.48%, 
95% CI 72.53%, 75.61%). The mean PRISMA score for Cochrane reviews was 85.19% (SD 5.03%, 
95% CI 83.79%, 86.59%) and the mean PRISMA score for non-Cochrane reviews was 69.59% (SD 
8.60%, 95% CI 68.09%, 71.09%). This difference was statistically significant (mean difference 
15.50% (95% CI 13.58%, 17.62%; p<0.00001). The mean PRISMA score for orthodontic papers 
was 75.07% (SD 10.36%, 95% CI 72.32%, 77.82%), for periodontic papers it was 74.91% (SD 
7.96%, 95% CI 72.80%, 77.03%), for preventive dentistry papers the means score was 71.50% 
(SD 13.73%, 95% CI 67.22%, 75.78%) and for endodontic papers the mean score was 74.20% (SD 
9.37%, 95% CI 70.33%, 78.07%). The differences between these scores was not statistically 
significant (p = 0.851). There was a weak negative linear relationship between the age of a 
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Cochrane review and its PRISMA score, indicating a small improvement in compliance with the 
PRISMA guidelines over time. This was statistically significant (p = 0.019).  There was also a weak 
negative linear relationship between the age of a non-Cochrane review and its PRISMA score but 
this was not statistically significant (p=0.422). The age of a paper, the speciality it belonged to 
and the type of review (Cochrane versus non-Cochrane) accounted for 46.5% of the variability in 
the final PRISMA score. 
Conclusions: The compliance of systematic reviews and meta-analyses with the QUOROM and 
the PRISMA guidelines was highly variable. There were significant differences between the 
PRISMA scores of non-Cochrane reviews and Cochrane reviews with the latter scoring more 
highly. There was also a slight increase in the compliance of Cochrane reviews over time, which 
was statistically significant. Although the speciality of orthodontics had the highest mean 
PRISMA score, there were no significant differences between the four specialities. 
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Introduction  
 
In the literature there are two types of research that are recognised: primary research and 
secondary studies. Systematic reviews and meta-analyses fall into the category of secondary  
research and can be described as overviews that review a body of data and in the case of a 
meta-analysis perform a statistical analysis to combine the results of primary studies. If 
conducted well they can allow a more objective appraisal of research evidence and may explain 
the heterogeneity between the results of different studies1. Systematic reviews and meta-
analyses are considered to provide the highest level of evidence because they combine the 
results of randomised control trials, the ‘gold standard’ method of research for comparing the 
relative effectiveness of competing interventions. Consequently the sample size is increased 
which in turn increases the statistical power and the validity of the results obtained2. They have 
been classified by the Centre for Evidence Based Medicine as level 1a evidence.3 
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Figure 1 Hierarchy of evidence (modified from 4) 
 
However, as with all types of research, systematic reviews and meta-analyses are not without 
their shortcomings. It has been found that a deficiency in their methodology can produce 
inflated or incorrect conclusions and hence an attempt was made in 1999 to improve the quality 
of reporting systematic reviews and meta-analyses by the instigation of the QUOROM 
statement.5 The QUOROM statement consists of a set of guidelines that comprise all the factors 
that should be included in a high-quality systematic review or meta-analytic paper5. Since its 
publication there have been a number of articles in the medical literature that have looked at 
the compliance of systematic reviews with the QUOROM guidelines.6-16 However at present 
there are no studies in the dental literature that have compared the quality of papers before 
and after the publication of the QUOROM statement. 
 
 
Meta-analyses/ 
Systematic 
Reviews 
Randomised 
Controlled Trials 
Experimental Design 
Cohort Control Studies 
Case-control Studies 
Case Series/ Case Reports 
Personal Communication 
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Systematic Reviews and Meta-analyses: Are they synonymous? 
 
While the two terms are often used interchangeably, it is important to distinguish between 
meta-analyses and systematic reviews. 
 
                          
Figure 2 Systematic reviews and meta-analyses 
 
A systematic review is “an overview of primary studies which contains an explicit statement of 
objectives, materials and methods and have been conducted according to explicit and 
reproducible methodology” 17 in order to limit bias. The term ‘systematic review’ refers to the 
whole process of data collection and analysis and all available evidence is included. A meta-
analysis may be included in the results section of a systematic review and it is usually the final 
step in conducting such a review but it is not always necessary or appropriate to do so. There 
are several advantages of systematic reviews and these include minimum bias in identifying and 
rejecting studies as well as rigorous methodologies, which ensure that more accurate 
conclusions can be drawn. Pooling the results of studies allows the combining of vast amounts 
of information and this may enable the early identification of potentially effective therapeutic 
measures and thus their rapid application. 
 
On the other hand a meta-analysis is a mathematical or statistical analysis that “combines or 
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integrates the results of several independent clinical trials considered by the analyst to be 
combinable”.18 As little as two primary clinical trials may be used to conduct a meta-analysis and 
it is fundamental that all studies included have addressed the same hypothesis using similar 
techniques. In other words a meta-analysis is possible without conducting a systematic review 
beforehand, although this is generally not good practice and an unbiased systematic review is a 
good way to start. A meta-analysis is conducted in two stages. The first stage consists of data 
extraction and the second stage constitutes evaluating the appropriateness of combining these 
data to obtain a point estimate of treatment effect. It is not valid to combine quantitative results 
from different studies, a weighted average is calculated after looking at the results of each 
study. Meta-analyses potentially offer several advantages such as the provision of a systematic 
method for synthesising evidence and the provision of quantitative overall results from 
individual studies. They also reduce the need for continued studies and allow questions to be 
addressed and answered that would not have been possible in individual studies due to their 
small sample size. 
The Cochrane Collaboration  
 
The Cochrane Collaboration is an international organisation that is made up of health care 
professionals, physicians, researchers and consumers. Its main aim is to “prepare, maintain and 
promote the accessibility of systematic reviews in all areas of health care”. 19,20 Initially, a study 
was conducted in 1974, based on the writings of British Epidemiologist Archie Cochrane who 
had stressed the importance of having access to all of the available evidence in health care. 21  
 
Later on the British National Health Service provided funding which facilitated the establishment 
of the first “Cochrane Centre” in 1992. This led to the formation of six more Cochrane Centres 
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by 1994 and in 1995 the Cochrane Collaboration was officially registered as a company and 
charity. At present, 52 Collaborative Review Groups are responsible for most of the work done 
by the Cochrane Collaboration which is mainly the preparation and maintenance of Cochrane 
reviews. The methods used to prepare these Cochrane reviews are under constant scrutiny and 
various Methods Groups undertake the task of ensuring that rigorous and systematic 
methodologies are used to provide a high standard of reporting them. 
 
The output of the Cochrane Collaboration can be found online in the Cochrane Library,21  which 
is updated quarterly. The Cochrane Library contains several databases including the Cochrane 
Database of Systematic Reviews (CDSR), the Cochrane Central Register of Controlled Trials 
(CENTRAL) and the Cochrane Review Methodology Database (CRMD). The CDSR is the primary 
output of the Cochrane Collaboration and contains systematic reviews produced by the 
collaboration itself. The CENTRAL contains a bibiliography of trials that have been downloaded 
from other databases such as MEDLINE, EMBASE and LILACS in combination with results of hand 
searching journals and conference reports. The CRMD, on the other hand, contains a 
bibliography of books and articles that deal with evaluating effects of health care. 
Methodologies of Systematic Reviews and Meta-Analyses 
 
Systematic reviews and meta-analyses require a lot of intensive labour to produce them. It is 
important for researchers to demonstrate expertise not only in the subject they are reviewing 
but also in the methodology required to conduct such reviews. The rules of evidence-based 
medicine must be followed and it is especially necessary that methodology being used is 
systematic.  
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With the recent rapid increase in the number of systematic reviews and meta-analyses in the 
literature it has become increasingly apparent that not all of these reviews are truly systematic 
in nature and many of them lack rigour in their methodology, which may result in bias leading to 
inaccurate conclusions and consequently incorrect application of the results obtained. One of 
the main reasons for potential bias is the fact that although systematic reviews and meta-
analyses are considered to provide the highest level of evidence, they remain studies which are 
both retrospective and observational. It is because of these disadvantages that it is crucial for 
these reviews to be constantly monitored and evaluated in order to guarantee a high standard 
of reporting so that bias is limited and results can be correctly applied to clinical practice. 
Assessing Systematic Reviews and Meta-Analyses 
 
Once the importance of evaluating systematic reviews and meta-analyses became recognised, 
researchers set out to find ways in which these studies could be assessed. Several papers were 
published that subjectively evaluated reviews while others produced generic checklists and 
guidelines that allowed a more systematic and objective appraisal. 22-27 
 
Oxman and Guyatt22 developed a set of guidelines in 1991 to evaluate review articles in the 
literature. They named their guidelines the Overview Quality Assessment Questionnaire 
(OQAQ), which consists of a checklist that included nine items that can be scored as ‘done’, 
‘partially done/cannot tell’ or ‘not done’ and a tenth item requiring a summary evaluation. The 
authors used the questionnaire to assess the quality of 36 published review articles. The 
sensitivity of OQAQ was evaluated by nine assessors who were faculty members at the 
Department of Clinical Epidemiology and Biostatistics and it was found that reviews that scored 
higher on the OQAQ had employed more rigorous methodologies. It was therefore concluded 
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that the questionnaire was a valid tool for assessing reviews. 
 
In 1993 a program was established known as the Critical Appraisal Skills Program (CASP) which 
aimed to enable individuals to develop the skills necessary to make sense of and critically 
evaluate research evidence and use that knowledge in practice.23 Based on a paper published in 
1994 entitled “User’s guide to the medical literature: How to use an overview” 24 the CASP 
produced a set of guidelines for systematic reviews and meta-analyses that would enable the 
reader to critique a review and get a better idea about its quality. The CASP guidelines 
concentrate on three main issues which are the validity of the study, the accuracy of the results 
and finally their applicability.23 They consist of a series of ten questions where eight of the 
questions may be answered with ‘yes’, ‘no’, or ‘can’t tell’ and the remaining two questions 
require more detailed responses. 
 
Del Mar and Glasziou wrote a Cochrane review about “Antibiotics for Sore Throat” in 1999 and 
devised the Glasgow Appraisal Tool.25 This tool is also a checklist with ten questions that 
assesses the validity of both systematic reviews and meta-analyses. The questions mainly look at 
the inclusion criteria for studies, the appropriateness of combining results, their overall 
precision and whether all the important outcomes are considered. 26 
 
Another tool that is available for the assessment of reviews is provided by the Aggressive 
Research Intelligence Facility (ARIF). ARIF is a specialist unit that is based in Birmingham and it 
aims to improve the incorporation of research evidence into healthcare decisions.27 The tool 
produced by the unit begins with three screening questions which allow the appraiser to assess 
the review quickly, followed by another thirteen questions that allow the evaluation of the 
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review in more depth. 
Other checklists include those constructed by Blettner, Cook, Geller, Goldschmidt, Meinert, 
Nony, Pogue and Sacks and these checklists vary in length and complexity ranging from  a few 
with ten items to one containing 101 items.21 Despite the construction of many quality 
assessment tools, there is a large variation in the quality of the instruments themselves and 
each one of them has different advantages and disadvantages depending on the criteria used to 
develop it. 
 
Table 1 Critical Appraisal Tools for Systematic Reviews 
Name Type Quality of: Number of 
Items 
Reference 
OQAQ Checklist Report and 
method 
9 Oxman and 
Guyatt (11) 
CASP Checklist Report 10 Oxman and 
Guyatt (13) 
Glasgow Checklist -  10 Glasziou (14) 
ARIF Checklist Report and 
method 
12 Birmingham 
 
The QUOROM Statement 
 
In 1996 the CONSORT statement was published in an effort to improve the standard of reporting 
randomised controlled trials after it was suggested that the standard of reporting them was 
poor.28 The guidelines included in this statement provided a very meticulous framework that 
helped authors to publish high quality reports of RCTs. Even though several guidelines already 
existed that allowed the evaluation of systematic reviews and meta-analyses, they lacked the 
thoroughness of the CONSORT statement and so a conference was held in an attempt to devise 
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a similar tool that would comprehensively help researchers to improve the quality of reporting 
reviews. It was attended by clinical epidemiologists, clinicians, statisticians and researchers, who 
conducted meta-analyses, as well as editors who had an interest in systematic reviews. The 
conference led to the publication of the QUOROM statement in 1999.5 The QUOROM statement 
stands for the Quality Of Reporting Of Meta-analyses and consists of a checklist and a flow 
diagram. The checklist is made up of eighteen items, in table format, that comprise all the 
factors that should be included in a high-quality meta-analysis or systematic review. The items 
are mainly related to the abstract, methods and results sections of a systematic review of 
randomised controlled trials and eight of these items are evidence based. Adhering to these 
guidelines ensures that the authors pay attention to detail and adequately report relevant 
information regarding the search strategy, paper selection, validity assessment, data 
abstraction, study characteristics and quantitative data synthesis.5 The flow diagram details the 
selection process by which randomised controlled trials are initially selected and finally either 
discarded or included in the systematic review. 
 
The QUOROM statement is the ‘gold standard’ in evaluating the standard of reporting 
systematic reviews due to a large portion of it being evidence based, meaning that the inclusion 
of many items in the checklist was based on research evidence. This implies that any systematic 
review or meta-analysis that has failed to comply with a certain item from the checklist will 
potentially have biased results. The guidelines were formed after a systematic review of 
systematic reviews was conducted and also after an expert panel consensus conference that 
employed a modified Delphi approach to analyse systematic reviews. The QUOROM statement 
was also pre-tested and modified afterwards to ensure its validity as a tool to assess the quality 
of systematic reviews and meta-analyses.21 
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When compared to the QUOROM statement, other scales and checklists have been found to 
focus on the methods section of a systematic review while neglecting other aspects. Out of all of 
the available instruments, only 5% (one checklist) looked at the title of a systematic review, 10% 
evaluated the abstract, 62% critiqued the introduction, 57% looked at data abstraction and 52% 
stressed the importance of including a description of the primary studies included in the 
review.21 
 
Quality Assessment of Systematic Reviews and Meta-analyses: A Review of the 
Literature 
 
As mentioned previously, even before the conference that led to the publication of the 
QUOROM statement, many tools for critical appraisal of systematic reviews and meta-analyses 
were being used to assess the standard of reporting them. One paper looked at meta-analyses 
in particular and recognised the importance of study design in providing accurate results. 29 The 
authors found that many of the previous meta-analyses lacked consistency and there was some 
heterogeneity of study outcomes, which led to inappropriate pooling of results and ultimately 
incorrect conclusions. They devised a set of guidelines to assess meta-analyses based on their 
discussion of the design and statistical issues. Other studies primarily looked at the extent to 
which heterogeneity was evaluated in meta-analyses and they showed that only 45% to 68% of 
meta-analytic procedures did tests for heterogeneity. 21 
 
In 1987 a study was conducted to assess the quality of 86 published meta-analyses.30 The 
articles were assessed based on 23 items from six content areas that were considered to be 
necessary in meta-analytic procedures and it was found that only 28% of these meta-analyses 
included all six content areas. This study was subsequently updated in 1996 and included meta-
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analyses published since 1987 and it was concluded that there had been very little improvement 
in the standard of reporting of meta-analyses.31 
 
In 2005, meta-analyses, in the general surgical literature, were critically evaluated using 
OQAQ.21 Papers, published between 1997 and 2002, were assessed and 487 potentially relevant 
papers were identified from MEDLINE. Out of these 51 met the inclusion criteria and they were 
subsequently critically appraised using the questionnaire. It was discovered that most studies 
exhibited deficiencies in their methodologies and it was postulated that this could be due to a 
lack of external collaboration and a lack of experience in conducting meta-analyses.  
 
In another attempt to assess the quality of systematic reviews, four different systematic 
reviews, that had been published on the effect of Vitamin E on the cardiovascular system, were 
reviewed.33 While the question posed in each of these four reviews was the same, the 
methodologies used in the identification and selection of studies were different and this led to 
very contradictory results. Two reviews concluded that Vitamin E did not benefit the 
cardiovascular system, one review found no correlation between Vitamin E and the 
cardiovascular system and the final review claimed that the vitamin was in fact harmful in high 
doses.  
 
A further study on Cochrane reviews, published in 2001,34 evaluated their quality. Although this 
was following the emergence of the QUOROM guidelines, the authors looked at Cochrane 
reviews from 1998, before the guidelines were published and used a fairly subjective evaluation 
process without any systematic method of assessing the reviews. Reviews were rated as having 
or not having major problems and the reasons for this were documented in detail. The study 
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concluded that Cochrane reviews only have minor problems if any and these problems tend to 
over-estimate the benefit of the therapeutic measure being looked at. 34  
 
Meta-analyses in occupational epidemiology have also been assessed in order to identify the 
major issues that may affect their quality.35 Relevant articles were searched using several 
electronic databases and ultimately 60 articles were selected for analysis. More than half of the 
meta-analyses investigated the heterogeneity of studies, however eight of these studies used 
meta-analysis models even though they had significant heterogeneity. Most of the meta-
analyses combined the results of all the primary studies they selected even though these studies 
varied immensely in the amount of information on exposure. The authors encouraged the 
proper exploration of heterogeneity so that the standard of reporting in occupational 
epidemiology could be improved. 
 
The strengths and limitations of meta-analyses, based on aggregate data, have also been 
investigated.36  All meta-analyses identified from MEDLINE, relating to cancer, were classified as 
either utilising individual patient data or summary or aggregate data. The vast majority of 
studies were found to be based on aggregate data and the authors saw this as a limiting factor. 
They concluded that whenever possible, individual patient data should be used due to their 
numerous advantages. The authors also concluded that aggregate patient data continues to be a 
part of most of the systematic reviews produced by the Cochrane Collaboration, the U.S 
Preventive Services Task Force and several other professional societies. 
 
The standard of reporting Cochrane reviews with the standard of systematic reviews and meta-
analyses published in paper-based journals has been explored.37 The Cochrane reviews were 
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identified from the Cochrane Library and the paper-based journals were selected from 
MEDLINE. Only papers published in 1995 were identified for inclusion in the study and all 36 
Cochrane reviews were included whereas 39 articles were selected from those found in 
MEDLINE. When this study was conducted, the QUOROM statement had not yet been published 
so the authors looked at the factors they thought were critical in a high quality review, including 
the number of authors, trials and patients included in the reviews as well as the trial sources, 
inclusion and exclusion criteria, language restrictions, primary outcome, trial quality assessment, 
heterogeneity testing and effect estimates. The authors found that while the papers selected 
from MEDLINE had more authors, trials and patients, the Cochrane reviews more thoroughly 
described the inclusion and exclusion criteria, assessed trial quality, avoided language 
restrictions, and updated their articles. It was concluded that Cochrane reviews employed 
superior methodologies and updated their reviews more often than systematic reviews and 
meta-analyses published in paper-based journals.  
Quality Assessment using the QUOROM Guidelines 
 
Recently studies have emerged in the literature, which have evaluated the quality of reporting 
as well as the compliance of systematic reviews and meta-analyses with the QUOROM 
statement6-16 and in general it seems that much improvement has yet to be achieved. In 2005, 
one study tested the compliance of meta-analyses in the critical care literature with the 
QUOROM statement.6 Studies published before and after the QUOROM statement were 
compared. 139 meta-analyses were included in the study and it was found that their overall 
quality was poor as only 30% had minimal flaws. Problems were found in the key parts of 
conducting a meta-analysis such as performing a literature review, limiting bias in the selection 
process and correctly referring to the validity of the chosen papers. When the papers written 
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before the QUOROM guidelines and the ones written after it were compared, an improvement 
was found. 
 
Another study7 showed that systematic reviews of traditional Chinese medicine were of low 
quality, as they did not follow guidelines outlined in the QUOROM statement rendering their 
results inconclusive and unreliable. On the other hand, a study looking at the quality of 
systematic reviews in the Cochrane Neonatal Review Group found that there was, in fact, a 
significant improvement in the quality of systematic reviews after the publication of the 
QUOROM statement.8  
 
Hou et al., undertook a quality appraisal of systematic reviews and meta-analyses of pneumonia 
in China.30 Two reviewers who were blinded to the authors analysed 326 reviews using the 
QUOROM statement as a guideline. Out of a possible 18 items that could be addressed, seven 
articles addressed ten items, five articles addressed two items and four papers addressed two 
items. It was concluded that the quality of reviews in the Chinese literature relating to 
pneumonia was weak in some aspects such as defining data sources, selection, searching, 
validity assessment, review methods and study characteristics.  
 
The quality of systematic reviews used in oncology practice was evaluated in another study.10 
The authors applied the QUOROM guidelines to all reviews related to breast and colon cancer 
prevention and therapy. Eighty reviews were selected and assessed and the results showed that 
29% of the reviews did not even match the definition of a systematic review. Twenty-one 
percent of the reviews did not adequately describe the searching methods employed and 70% 
were not systematic and were of very low quality.  The authors warned oncologists that they 
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were in fact relying on poorly written documents and improvement was necessary.  
 
A review of meta-analyses dealing with pharmacotherapy of post-traumatic stress disorder also 
assessed their standard using the QUOROM guidelines.11 It was shown that the quality of meta-
analyses was acceptable in the PTSD literature.  
 
Bereza et al., evaluated the compliance of meta-analyses of anxiety disorders with the QUOROM 
guidelines.12 They identified 136 papers from several electronic databases that were published 
between 1995 and 2007 but only 16 of them met the inclusion criteria. Results of this study 
showed that the QUOROM quality score was approximately 62% (SD19%). The lowest scores 
were obtained for the results sections of the meta-analyses, whereas the introduction and 
discussion sections scored the highest. The overall quality was 58% (SD 28%). It was concluded 
that the standard of reporting was below average and significant improvement was required. 
 
Another study looked at the compliance of Health Technology Assessments (HTA) with the 
QUOROM guidelines.13 All systematic reviews of therapeutic interventions in HTA that had been 
published between 2001 and 2005 were included in the study, resulting in a total of 87 papers. 
The results showed that 49% of all systematic reviews used a study selection flow diagram. It is 
interesting to note that when only systematic reviews, containing a meta-analysis were 
analysed, compliance with the QUOROM guidelines was found to be 32%.13 Only 23% of all 
systematic reviews included a diagram that expressed the relationship between citations and 
studies. 14  
 
A random sampling study of meta-analyses in the medical literature was conducted in 2008 
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where a random sample of 161 papers was identified from MEDLINE and assessed according to 
the QUOROM guidelines.14 The mean QUOROM score was 12.3 out of a possible 18 and this 
mean increased significantly from 10.5 in 2000 to 13.0 in 2005, indicating an improvement in the 
compliance with the QUOROM statement over time. The mean score of Cochrane reviews was 
14.2 whereas the score for paper-based articles was 11.7. This indicates that Cochrane reviews 
exhibited a higher standard of reporting when compared with published papers. However, when 
looked at in detail, it became evident that Cochrane reviews scored higher mainly in the abstract 
section but they obtained lower scores in their trial flow. The authors encouraged an 
improvement in the standard of reporting articles published in the future. 
 
Shea et al., compared the standard of reporting of original systematic reviews with updated 
Cochrane reviews in order to determine whether the updating process led to an improvement in 
their quality.15 Fifty-three Cochrane reviews that were published in 2002 were included in the 
study and the updated and original versions were assessed using the QUOROM guidelines. It 
was concluded that the quality of reporting Cochrane reviews improved in some areas after they 
were updated. However, even though the standard of reporting increased on some individual 
items there was no overall improvement seen in the updated articles and the methodologies 
were for the most part consistent. 
 
Shea et al also compared Cochrane reviews and systematic reviews published in paper-based 
journals.16 Cochrane reviews were found to have a higher standard of reporting in some aspects 
whereas paper-based reviews had a higher standard in reporting others. The overall quality 
however was found to be low.  
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Quality Assessment in the Orthodontic Literature 
While there has been a substantial increase in the number of systematic reviews and meta-
analyses published in the literature, there remains a paucity of such studies conducted in 
orthodontics and it was found that between 1966 and 2002, while the medical literature had 
8418 published meta-analyses, the orthodontic literature had only 13. 38 This may be because it 
is not possible to perform a meta-analysis due to a lack of appropriate primary studies that can 
be included for data synthesis. 
 
As of yet there is one paper that has critically evaluated the quality of reporting meta-analyses 
in the orthodontic literature. The study was conducted by Papadopoulos and Gkiauris and they 
searched several electronic databases and hand searched journals in order to identify all meta-
analyses in Orthodontics.39 They retrieved 98 papers initially but only 16 papers met the 
inclusion criteria and so only those meta-analyses were included in the evaluation. It was found 
that, in general, some of the published articles incorporated appropriate methodologies and 
adequate quantitative data synthesis whereas others lacked rigorous methodologies such as 
biases in the selection process of the studies, lack of sufficient information to permit 
repeatability by other researchers and a lack of high-quality research leading to small sample 
sizes. Out of the 16 papers assessed the ones that provided the best level of evidence were 
those discussing maxillary protraction treatment,40,41 the treatment of posterior crossbites,42  
the repeatability of lateral cephalometric measurements,43 the relationship between anterior 
tooth injuries and size of the overjet,44 correlation of external apical root resorption with 
treatment-related factors45 and the prevalence of tooth agenesis.46 Each paper was appraised 
individually according to where the authors thought their deficiencies lay but there was no 
assessment of the papers using specific guidelines such as those found in the PRISMA or 
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QUOROM statements. 
The PRISMA Statement 
 
In 2009, the QUOROM statement was updated to the PRISMA statement (Preferred Reporting 
Items of Systematic reviews and Meta-Analyses).48 This was done in order to address the 
advances in the science of systematic reviews. The PRISMA statement consists of a 27-item 
checklist and a flow diagram, similar to the one found in the QUOROM statement.  
Because the guidelines have only changed recently, only one paper so far has looked at the 
compliance of systematic reviews and meta-analyses with the PRISMA statement.49 
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Aim  
 The overall aim of this study was to assess the quality of systematic reviews and meta-
analyses in the dental literature. 
Objectives 
Primary Objectives 
 
 To assess the compliance of systematic reviews and meta-analyses in the orthodontic, 
periodontal, preventive dentistry and endodontic literature with the PRISMA guidelines 
 To assess whether there has been an improvement in the quality of systematic reviews and 
meta-analyses over time 
Secondary Objectives 
 To determine whether or not there is a difference in the perception of quality of the review 
when scoring with the QUOROM guidelines or the PRISMA guidelines  
 To determine if there is a difference between the compliance of reviews with the PRISMA 
statement amongst the specialities 
  To determine if there is a difference between the standard of Cochrane reviews and non-
Cochrane systematic reviews and meta-analyses 
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Null Hypotheses 
Primary hypothesis 
 There is no correlation between the compliance of reviews with the PRISMA guidelines and 
the year of publication of those reviews 
 
Secondary Hypotheses 
 There is no difference in the compliance of systematic reviews and meta-analyses with the 
QUOROM statement and the PRISMA statement. 
 There is no difference in the compliance of Cochrane reviews and non-Cochrane systematic 
reviews with the guidelines of the PRISMA statement. 
 There is no difference between the specialities in their compliance with the PRISMA 
guidelines. 
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Material and Methods 
Study Design 
This was a retrospective observational study. 
Sample 
Sample Size Calculation 
The sample size calculation was originally based on expected differences between QUOROM 
scores before and after the publication of these guidelines and was derived from the raw data 
from a systematic evaluation of the quality of meta-analyses in the critical care literature.6 The 
calculation was performed using Altman’s nomogram and it was found that to achieve 80% 
power, with a 0.05 two-sided significance level, 165 papers were needed in the present study. 
As a preliminary search of systematic reviews in the orthodontic literature failed to return a 
sufficient number of papers the decision was made to include three other specialties in the 
study, namely periodontics, preventive dentistry and endodontics. 
Papers 
The following papers were included in the study: 
 Systematic reviews and meta-analyses pertaining to any of the specialities of 
orthodontics, periodontics, preventive dentistry and endodontics 
 All original Cochrane reviews in the Cochrane library that were found to be relevant 
to these four specialities 
 Updated versions of these Cochrane reviews, if available 
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Time Periods 
Originally the intent of this study was to include the five years preceding the publication of the 
QUOROM guidelines and the ten years following it, but a sparsity of papers published before the 
year 1999 necessitated the omission of any time period restrictions and thus all systematic 
reviews and meta-analyses were included irrespective of publication date.  
Search Methods for Identification of Studies 
Electronic Searches 
An advanced computerised search was conducted of the Cochrane library. Four separate 
searches were performed, one for each speciality. To identify orthodontic papers the term 
‘orthodontics’ was entered as a MeSH descriptor and all trees were exploded. The search results 
displayed papers from five different databases. All papers identified within the Cochrane 
Database of Systematic Reviews and the Database of Abstracts of Reviews of Effects were 
included in the study. The Cochrane Database of Systematic Reviews displays the most up-to-
date version of Cochrane reviews so each Cochrane review was further inspected for any earlier 
versions and these were included as well. The same search strategy was repeated for the other 
three specialities with the terms ‘periodontics,’ ‘preventive dentistry’ and ‘endodontics’ entered 
separately for each search. This review did not have any language restrictions. The date of the 
last search was January 31st, 2011. 
Searching other resources 
No other search strategies were employed. 
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Data Collection and Analysis 
Data were collected on each paper for both the QUOROM and the PRISMA guidelines. A 
checklist was compiled for each, based on the published statement. 
For the QUOROM statement the guidelines were further divided into a checklist of 63 items. For 
each criterion except for the ones pertaining to the inclusion and exclusion criteria in the 
methods section, a score of one was awarded where the criterion was met and score of zero 
where it was not. Items 28-31 relate to the inclusion criteria and where at least three out of four 
criteria were met one point was awarded. If two or less criteria were met, the score for the 
inclusion criteria was zero. Items 32-35 relate to the exclusion criteria and again a score of one 
was only awarded if at least three out of these four criteria were met. The maximum score for 
each paper was therefore 57. In some instances a specific criterion was not applicable to the 
study and in this case, instead of a score the term N/A (or non-applicable) was appointed for 
that item in the score sheet. To allow direct comparisons between the reviews the final score for 
each paper was calculated as a percentage. 
Final score =  Total points achieved x 100 
   (57 - number of N/As) 
The maximum attainable score for each study was 100% and this indicated that the reporting of 
the systematic review or meta-analysis abided by all the criteria recommended by the QUORUM 
statement. 
For the PRISMA statement the guidelines were again used to construct a checklist of 63 items. 
The rules for scoring were similar to the QUOROM checklist but no items were grouped so for 
every item a score of one was possible where the criterion was met. This enabled each paper to 
 31 
achieve a maximum score of 63. Again, the final score was calculated as a percentage. 
Final score =  Total points achieved x 100 
   (63 - number of N/As) 
Pilot Study 
A pilot study was conducted on a ten percent, randomly selected sample of the identified 
papers to determine inter-examiner reliability for the PRISMA checklist.  A list of papers was 
prepared by JEH using a random number generator and these papers were scored separately by 
the supervisor, JEH, and the examiner, NR. Inter-examiner agreement was determined by 
calculating a percentage agreement kappa value for each item on the checklist and where a 
criterion scored less than 0.80, out of a possible maximum score of 1.00, the description of the 
item was modified, after discussion with the supervisor, to clarify the assessment criteria. The 
item was then rescored until an acceptable level of reliability was obtained with a kappa score 
of 0.80 or above. 
Data Collection 
The data were entered into two Microsoft Excel® spreadsheets (Microsoft Office 2003, 
Microsoft Corporation, Redmond, WA98052-7329, USA), one for the QUOROM checklist and 
one for the PRISMA checklist. For the QUOROM checklist the spreadsheet used was made up of 
57 columns representing the criteria being assessed and each row represented the systematic 
reviews and meta-analyses included in the study. For the PRISMA checklist the spreadsheet used 
consisted of 63 columns for each criterion and a row for each paper assessed. Due to the time 
taken to assess a paper a maximum of three papers were scored at a time to prevent examiner 
fatigue and hence reduce scoring errors. 
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Reliability 
To attain an acceptable level of intra-examiner agreement for both the QUOROM checklist and 
the PRISMA checklist a reliability study was conducted in addition to the main study. A list of ten 
percent of the papers was prepared using a random number generator and data on these 
papers were collected on both checklists by NR six months after the completion of data 
collection for the entire sample. NR was blinded to the initial results whilst re-examining the 
papers. A kappa score was calculated for each item on the two checklists, with the highest 
possible score being 1.00, indicating perfect agreement. 
Statistical Analysis 
SPSS and RevMan 
Comparison of checklists 
 
The QUOROM and PRISMA checklists were compared using the Bland and Altman test to 
determine whether or not the guidelines were interchangeable. Further statistical analyses were 
conducted on the PRISMA checklist scores as these guidelines are more recent. 
Descriptive statistics  
Descriptive statistics were initially used to summarise the data obtained for the PRISMA 
guidelines. The mean percentage score, standard deviation, 95% confidence interval, median, 
range and interquartile range were calculated for the following data sets: 
 The data for the total sample 
 The total sample of Cochrane reviews 
 The total sample of non-Cochrane reviews 
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 The total sample of orthodontics reviews 
 The orthodontic Cochrane reviews 
 The orthodontic non-Cochrane reviews 
 The total sample of periodontic reviews 
 The periodontic Cochrane reviews 
 The periodontic non-Cochrane reviews 
 The total sample of preventive dentistry reviews 
 The preventive dentistry Cochrane reviews 
 The preventive dentistry non-Cochrane reviews 
 The total sample of endodontic reviews 
 The endodontic Cochrane reviews 
 The endodontic non-Cochrane reviews 
Comparisons of scores 
Normality of the data was determined using visual tests such as the Q-Q plot and the P-P plot in 
addition to Shapiro-Wilks’ test for normality and the Kolmogorov-Smirnov test. These tests 
indicated that the data were not normality distributed so non-parametric tests were used to 
analyse the data. Data were considered to be statistically significant when p<0.05. 
Weighted mean differences were used to make several single comparisons. Each set of data 
were weighted according to sample size. The following single comparisons were made: 
1.  All Cochrane reviews vs. all non-Cochrane reviews 
2. All orthodontic Cochrane review papers vs all orthodontic non-Cochrane reviews 
3. All periodontal Cochrane reviews vs. all periodontal non-Cochrane reviews 
4. All preventive dentistry Cochrane reviews vs. all preventive dentistry non-Cochrane reviews 
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5. All endodontic Cochrane reviews vs. all endodontic non-Cochrane reviews 
Kruskall-Wallis tests were used to compare the four specialities i.e: orthodontics vs periodontics 
vs preventive dentistry vs endodontics 
It was not feasible to compare reviews published before and after the publication of the PRISMA 
statement, which were only published recently, as there was an insufficient number of papers 
published after the statement was issued. Similarly, a relatively small number of papers was 
published before the QUOROM statement in 1999 so it was not possible to compare reviews 
published before and after this statement was issued. Therefore, in order to determine whether 
or not there had been an improvement in the quality of reporting systematic reviews over time, 
each paper was first assigned an age at 31st January 2010 according to the year of publication. 
For example, a paper published in 2009 was appointed an age of one year, a paper published in 
2008 was two years old and so forth. The ages of the papers were then plotted against their 
PRISMA scores and a line of best fit was drawn. A Pearson correlation coefficient was calculated 
and this was used to establish if there was a relationship between the age of a paper and the 
score attained. The papers were then separated into Cochrane and non-Cochrane reviews, after 
which each group was plotted separately against age in order to determine if there was a 
difference in correlation coefficients between the two groups, which would indicate that one 
group was improving with time while the other was not. 
Finally, multiple linear regression was used to model the extent to which three predictor 
variables determined the final PRISMA score of a paper. These variables were: 
1. The type of paper (Cochrane or non-Cochrane). 
2. The speciality the paper was related to  
3. Age of paper 
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Results 
Sample Characteristics 
 
The search strategy identified 181 potentially relevant systematic reviews and meta-analyses 
across the four specialities. (Figure 2.) There were no systematic reviews or meta-analyses 
published before 1996 and the most recent systematic review included in the study was 
published in 2009. The earliest systematic review published in the literature was in the speciality 
of periodontics.  
 
Table 2 Year of publication of earliest systematic review by speciality 
 
 
Speciality Review Year 
Orthodontics  Orthodontic treatment for posterior crossbites 
 Occlusal treatments in temporomandibular disorders: a qualitative 
systematic review of randomised controlled trials 
 Therapeutic outcome assessment in permanent temporomandibular 
joint disc replacement 
1999 
1999 
1999 
Periodontics  Microbiological response to mechanical treatment in combination with 
adjunctive therapy: a review of the literature  
 
1996 
Preventive 
Dentistry 
 A systematic review of the effectiveness of health promotion aimed at 
improving oral health 
 
1998 
Endodontics  A systematic review of in vivo retrograde obturation materials 
 
2003 
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Figure 3 Flowchart of distribution of papers amongst the specialities 
 
 
Table 3 Number of Cochrane and non-Cochrane reviews in each speciality 
Speciality Cochrane Reviews Non-cochrane reviews 
Orthodontics 20 37 
Periodontics 9 48 
Preventive dentistry 13 29 
Endodontics  10 15 
 
 
 
 
 
 
 
 
181 reviews 
57 
orthodontics 
papers 
57 
periodontics 
papers 
42 preventive 
dentistry 
papers 
25 
endodontics 
papers 
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Pilot Studies 
Pilot to assess the validity of the search 
 
A ten percent sample of the papers identified by the search was analysed to establish if they 
were indeed systematic reviews or meta-analyses. The papers were numbered from one to 181 
and a random number generator was used by supervisor JEH to select 19 papers. The papers 
were assessed by examiner NR in accordance with the Cochrane Handsearchers’ Handbook. All 
19 papers met the criteria thus it was concluded that the search was accurate and all 181 papers 
were included in the study. 
 
Pilot to assess inter-examiner agreement 
 
A ten percent sample of the articles was selected using a random number generator by 
supervisor JEH resulting in a total of 19 papers. The 63-item PRISMA checklist was used to score 
these papers by JEH and NR, independently and in duplicate. For each item there were three 
possible scores: one, zero, or non-applicable. Inter-examiner agreement was assessed by 
tabulating the number of agreements and disagreements for each item and subsequently 
calculating a kappa value. Hence 63 kappa values were calculated and evaluated. An acceptable 
level of agreement was said to be attained when a kappa value of 0.80 or above was obtained, 
indicating at least 80% agreement.  
Out of the 63 items, six had relatively low kappa scores: 
 Item 7: mention of the participants in the abstract (kappa score 0.53) 
 Item 20: specification of the comparisons in the methods section (kappa score: 0.72) 
 Item  21: specification of the outcomes in the methods section (kappa score: 0.72) 
 Item  28: mention of the date last searched in the methods section (kappa score: 0.47) 
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 Item 29: presentation of the full electronic strategy for at least one database, including 
any limits used, so that it could be repeated (kappa score: 0.72) 
 Item 39: presentation of any assessment of risk of bias across studies (kappa score: 
0.53) 
Differences in scoring of these items were resolved by discussion between JEH and NR and 
comments were added to definitions of these six items to increase the accuracy of scoring. 
 
 
Table 4 Items with low Kappa scores 
Item  Descriptions Comments 
6 Abstract: mention of the participants Actual population looked at in each 
trial eg adolescents, II/1  
20 Methods: specification of the comparisons Compare to other group or control 
21 Methods: specification of the outcomes Detailed outcome measures, including 
measuring units 
28 Methods: mention of the date last searched Explicitly state date of last search, not 
just the time period included 
29 Methods: presentation of the full electronic strategy 
for at least one database, including any limits used 
Search terms not enough, table 
required with detailed strategy 
56 Discussion: presentation of any assessment of risk of 
bias across studies 
E.g. publication bias 
 
Following discussion these items were rescored and new kappa values were calculated which 
demonstrated very good inter-examiner agreement, so no further modification of the checklist 
was required. 
 
 
 39 
Pilot to assess intra-examiner agreement 
 
A ten percent sample of the papers was assessed for intra-examiner agreement. 19 papers were 
selected by the supervisor, JEH, using a random number generator and were rescored by NR six 
months after the completion of data collection for the main study. Both the QUOROM checklist 
and the PRISMA checklist were used to rescore the papers. Kappa values were calculated for 
each item on each of the checklists and a very high level of intra-examiner agreement was 
achieved indicating excellent reliability of the measurement tools.  
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Main study 
Assessing normality of the data 
 
Both the scores obtained for the QUOROM checklist and the PRISMA checklist were tested for 
normality. A variety of investigations were employed including diagrammatic representations of 
the distribution of the data, and two tests for normality, namely the Shapiro-Wilk and the 
Kolmogorov-Smirnov tests. (See Figures 3-6 and Table 5). The majority of the investigations 
indicated that the data were not normally distributed therefore non-parametric tests were used 
to analyse this data. 
 
 
 
Figure 4 Histogram of the frequency of each PRISMA score 
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Figure 5 Normal Q-Q Plot of PRISMA score 
 
 
Figure 6 Detrended normal Q-Q plot of PRISMA score 
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Figure 7 Boxplot of PRISMA score 
 
 
 
Table 5 Tests for normality 
 Kolmogorov-Smirnov Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
PRISMA Score 0.068 181 0.40 0.965 181 P<0.001 
 
Comparison of the checklists 
The Bland and Altman test was used to compare the scores of the QUOROM and the PRISMA 
checklists. The results of this test showed that there was a bias of -3.3, which was statistically 
significant (p<0.001). A visual analysis of the difference plot indicated that approximately 5% of 
the points lay outside the 95% limits of agreement. 
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Figure 8 Bland and Altman plot for interexaminer agreement 
 
 
 
Although there was bias between the two measurement tools which was statistically significant, 
save for a few outliers the QUOROM scores were consistently lower than the PRISMA scores by 
approximately 3 percent per score. 
Descriptive Statistics for the QUOROM and PRISMA guidelines 
In addition to calculating means, standard deviations and 95% confidence intervals for the data, 
medians, ranges and interquartile ranges were calculated as well because the data were not 
normally distributed. The mean overall score for the papers when assessed using the QUOROM 
checklist was 70.86% and the median was 72.00%. For the PRISMA checklist the mean overall 
score was 74.07% and the median was 75.00%. (Tables 6 and 7). 
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Table 6 Descriptive statistics for the QUOROM guidelines 
Statistic Value (%) 
Mean 70.86 
Standard Deviation 11.36 
95% Confidence Interval 69.20-70.86 
Median 72.00 
Minimum 37 
Maximum 89 
Range 52 
Interquartile Range 17 
 
 
 
 
Table 7 Descriptive statistics for the PRISMA guidelines 
Statistic Value (%) 
Mean 74.07 
Standard Deviation 10.48 
95% Confidence Interval 72.53-75.61 
Median 75.00 
Minimum 43 
Maximum 92 
Range 49 
Interquartile Range 16 
 
 
Highest and lowest scoring papers 
 
The highest score achieved by any paper was 92%. This was achieved by three orthodontic 
Cochrane reviews and one Cochrane review in periodontics. 
 
Orthodontics: 
1. Occlusal interventions for periodontitis in adults 
2. Occlusal adjustment for treating and preventing temporomandibular joint disorders (the 
updated version) 
3. Fluorides for the prevention of white spots on teeth during fixed brace treatment (the 
updated version) 
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Periodontics: 
1. Guided tissue regeneration for periodontal infra-bony defects 
 
The lowest score achieved by any paper was in the speciality of preventive dentistry, entitled: 
“Reviews of evidence on interventions to prevent dental caries, oral and pharyngeal cancers, 
and sports-related craniofacial injuries.” 
Comparison of Cochrane and Non-Cochrane Reviews 
 
Out of the 181 papers, 52 papers were Cochrane reviews and 129 were other systematic 
reviews or meta-analyses. The mean overall score for Cochrane reviews, assessed using the 
PRISMA checklist was 85.19% (SD 5.03). On the other hand the median score was 86.00%. The 
mean overall score for non-Cochrane reviews was 69.59% (SD 8.60) and the median score was 
69.00%. (See table 8). 
 
 
 
 
 
 
 
 
 
 46 
Table 8 Descriptive statistics for Cochrane and non-Cochrane reviews 
Statistic Cochrane Reviews Non-Cochrane Reviews 
Mean 85.19 69.59 
Standard Deviation 5.03 8.60 
95% Confidence Interval 83.79-86.59 68.09-71.09 
Median 86.00 69.00 
Minimum  65 43.00 
Maximum 92 90.00 
Range 27 47.00 
Inter-quartile range 5 10.50 
 
When the mean PRISMA score for Cochrane reviews was compared to the mean PRISMA score 
for non-Cochrane reviews using weighted mean difference, the difference in means was found 
to be statistically significant (p<0.00001, WMD 15.60, 95% CI 13.58, 17.62). (See figure 8). 
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Figure 8 Mean difference for mean PRISMA score of all Cochrane reviews and the mean PRISMA score of all non-Cochrane reviews 
Study or Subgroup
PRISMA Combined
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 15.15 (P < 0.00001)
Mean
85.19
SD
5.03
Total
52
52
Mean
69.59
SD
8.6
Total
129
129
Weight
100.0%
100.0%
IV, Random, 95% CI
15.60 [13.58, 17.62]
15.60 [13.58, 17.62]
Cochrane Non-Cochrane Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours non-Cochrane Favours Cochrane
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Differences amongst the specialities 
 
The specialities of orthodontics and periodontics had the highest total number of reviews 
published, while endodontics had the smallest number of published reviews. The greatest 
number of Cochrane reviews has been published in the orthodontic literature.  
The mean score for each speciality is as follows: 
1. Orthodontics mean score: 75.07% (SD 10.36) 
2. Periodontics mean score: 74.91% (SD 7.96) 
3. Preventive dentistry mean score: 71.50% (SD 13.73) 
4. Endodontics mean score: 74.20 (SD 9.37) 
 
Table 9 Descriptive statistics for PRISMA scores by speciality 
 Orthodontics Periodontics Preventive Dentistry Endodontics 
Mean 75.07 74.91 71.50 74.20 
Standard Deviation 10.36 7.96 13.73 9.37 
95% Confidence Interval 72.32-77.82 72.80-77.03 67.22- 
75.78 
70.33-78.07 
Median 73 75 74 80 
Minimum 57 57 43 57 
Maximum 92 92 89 87 
Range 35 35 46 30 
Inter-quartile Range 19 10.50 17.50 16.50 
 
Kruskall-Wallis Tests 
 
As can be seen above, when comparing the mean PRISMA score for each speciality it is evident 
that there were differences between them. The speciality of orthodontics scored the highest 
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with a mean score of 75.07%. Periodontics scored the second highest with a score of 74.91%.  
The lowest score belonged to preventive dentistry and was 71.50%. The mean score for 
endodontics was 74.20%, althought interestingly, endodontics had the highest median score. 
Nonetheless, the Kruskall-Wallis test showed that there were no statistically significant 
differences between the four specialities (p= 0.851, chi-square= 0.796, df=3). 
 
However, the percentage of Cochrane reviews in relation to the total sample, which had already 
been shown to score higher on average than non-Cochrane reviews, was different for each 
speciality. In orthodontics 35% of the papers were Cochrane reviews. In periodontics Cochrane 
reviews made up only 19% of all the papers, while in preventive dentistry they made up 31% 
and in endodontics 40% of the papers were Cochrane reviews. (Table 9). Due to this unequal 
distribution of Cochrane and non-Cochrane systematic reviews amongst the specialities these 
two groups were compared separately. 
 
Table 10 Distribution of Cochrane and non-Cochrane reviews amongst the specialities 
Speciality Cochrane Reviews Non-Cochrane Reviews Total 
Orthodontics 20 37 57 
Periodontics 9 48 57 
Preventive dentistry 13 29 32 
Endodontics 10 15 25 
 
Accordingly the Kruskall-Wallis test was used to first compare Cochrane reviews amongst the 
specialities. It was shown that there was a statistically significant difference between the mean 
scores of orthodontics, periodontics, preventive dentistry and endodontics (chi-square 9.88, df 
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3, p=0.0196). The highest mean score for Cochrane reviews was 87.22% and was found in the 
speciality of periodontics. Orthodontics came in second with a mean score of 85.35%. This was 
closely followed by preventive dentistry that had a mean score of 85.23% and the lowest mean 
score was in the speciality of endodontics and was 83.00%. 
 
Non-cochrane reviews were also compared using the test and once more there was a 
statistically significant difference between the specialities (chi-square 9.48, df=3, p=0.0235). 
Again, periodontics had the highest mean score which was 72.6%, followed by orthodontics 
(mean= 69.51%). The speciality of endodontics achieved a mean score of 68.33 and this time it 
was preventive dentistry that scored the lowest with a mean of 65.34%. 
 
 
Table 11 Mean scores for Cochrane and non-Cochrane reviews in each speciality 
Speciality Cochrane Reviews Non-Cochrane Reviews 
Orthodontics 85.35 (SD 7.15) 69.51 (SD 7.05) 
Periodontics 87.22 (SD 2.68) 72.6 (SD 6.31) 
Preventive Dentistry 85.23 (SD 3.09) 65.34 (SD 12.05) 
Endodontics 83 (SD 2.58) 68.33 (SD 7.35) 
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Orthodontics 
 
The mean score for orthodontic Cochrane reviews was 85.35% (SD 7.15). For other orthodontic 
reviews and meta-analyses the mean score was 69.51% (SD 7.05). (Table 12). Comparison of the 
means using the weighted mean difference showed a statistically significant difference between 
them (p< 0.00001, WMD 15.84, 95% CI 11.97, 19.71). (Figure 9). 
 
Table 12 Descriptive statistics for Cochrane and non-Cochrane reviews in orthodontics 
Statistic Cochrane Reviews Non-Cochrane Reviews 
Mean 85.35 69.51 
Standard Deviation 7.15 7.05 
95% Confidence Interval 82.01-88.70 67.16-71.86 
Median 87.50 68 
Minimum 65 57 
Maximum 92 87 
Range 27 30 
Inter-quartile range 3.75 11 
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Figure 9 Weighted mean difference for mean PRISMA score of Cochrane reviews and non-Cochrane in orthodontics 
 
 
 
Study or Subgroup
PRISMA Orthodontics
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 8.02 (P < 0.00001)
Mean
85.35
SD
7.15
Total
20
20
Mean
69.51
SD
7.05
Total
37
37
Weight
100.0%
100.0%
IV, Fixed, 95% CI
15.84 [11.97, 19.71]
15.84 [11.97, 19.71]
Cochrane Non-Cochrane Mean Difference Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours Non-Cochrane Favours Cochrane
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Periodontics 
 
Cochrane reviews in periodontics had a mean score of 87.22% (SD 2.68). Non-Cochrane reviews 
and meta-analyses had a mean score of 72.6% (SD 6.31). (Table 13). When these means were 
compared using the weighted mean difference it was shown that there was a statistically 
significant difference between the two (p< 0.00001, WMD 14.62, 95% CI 12.12, 17.12). (Figure 
10). 
 
 
Table 13 Descriptive statistics for Cochrane and non-Cochrane reviews in periodontics 
Statistic Cochrane Reviews Non-Cochrane Reviews 
Mean 87.22 72.60 
Standard Deviation 2.68 6.31 
95% Confidence Interval 85.16-89.28 70.77-74.44 
Median 87 73.50 
Minimum 83 57 
Maximum 92 90 
Range 9 33 
Inter-quartile range 4 8.75 
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Figure 10 Weighted mean difference for mean PRISMA score of Cochrane reviews and non-Cochrane reviews in periodontics
Study or Subgroup
PRISMA Periodontics
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 11.46 (P < 0.00001)
Mean
87.22
SD
2.68
Total
9
9
Mean
72.6
SD
6.31
Total
48
48
Weight
100.0%
100.0%
IV, Fixed, 95% CI
14.62 [12.12, 17.12]
14.62 [12.12, 17.12]
Cochrane Non-Cochrane Mean Difference Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours non-Cochrane Favours Cochrane
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Preventive Dentistry 
 
In preventive dentistry, Cochrane reviews had a mean score of 85.23% (SD 3.09) whereas other 
reviews had a mean PRISMA score of 65.34% (SD 12.05). (Table14). Comparison of the two 
means using weighted mean difference showed that there was a statistically significant 
difference between Cochrane and non-Cochrane reviews in this speciality (p<0.00001, WMD 
19.89, 95% CI 15.19, 24.59). (Figure 11). 
 
 
Table 14 Descriptive statistics for Cochrane and non-Cochrane reviews in preventive dentistry 
Statistic Cochrane Reviews Non-Cochrane Reviews 
Mean 85.23 65.34 
Standard Deviation 3.09 12.05 
95% Confidence Interval 83.37-87.10 60.76-69.93 
Median 86 67 
Minimum 81 43 
Maximum 89 86 
Range 8 43 
Inter-quartile range 6 20.50 
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Figure 11 Weighted mean difference for mean PRISMA score of Cochrane reviews and non-Cochrane reviews in preventive dentistry
Study or Subgroup
PRISMA Preventative
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 8.30 (P < 0.00001)
Mean
85.23
SD
3.09
Total
13
13
Mean
65.34
SD
12.05
Total
29
29
Weight
100.0%
100.0%
IV, Fixed, 95% CI
19.89 [15.19, 24.59]
19.89 [15.19, 24.59]
Cochrane Non-Cochrane Mean Difference Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours non-Cochrane Favours Cochrane
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Endodontics 
 
As with the other three specialities, in endodontics Cochrane and non-Cochrane reviews had 
different mean scores with Cochrane reviews scoring higher than other types of review articles. 
The mean score for Cochrane reviews was 83% (SD 2.58) and for other reviews the mean was 
68.33% (SD 7.35). (Table 14). Weighted mean difference was again used to test for significant 
differences between the means and it was found that there was indeed a statistically significant 
difference between them (p<0.00001, WMD 14.67, 95% CI 10.62, 18.72). (Figure 12). 
 
Table 15 Descriptive statistics for Cochrane and non-Cochrane reviews in endodontics 
Statistic Cochrane Reviews Non-Cochrane Reviews 
Mean 83.00 68.33 
Standard Deviation 2.58 7.35 
95% Confidence Interval 81.15-84.85 64.26-72.41 
Median 82.94 67 
Minimum 80 57 
Maximum 87 82 
Range 7 25 
Inter-quartile range 4 6 
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Figure 92 Weighted mean difference for PRISMA score of Cochrane reviews and non-Cochrane reviews in endodontics 
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Meta-analysis of mean scores for Cochrane and non-Cochrane reviews 
 
The results for the mean Cochrane and the mean non-Cochrane scores for each speciality were 
combined and a meta-analysis was performed to assess the overall difference in scores between 
the two types of reviews, while taking into account the different sample sizes for each speciality. 
There was no significant heterogeneity within the sample (p=0.26) so a random effects model 
was not required when comparing Cochrane and non-Cochrane reviews. When the results of 
each speciality were combined there was a statistically significant difference between the two 
mean scores (p<0.00001, WMD 15.59, 95% CI 13.86, 17.32). (Figure 13). 
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Figure 13 Meta-analysis of mean scores of Cochrane and non-Cochrane reviews 
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Changes in PRISMA scores with time 
As mentioned previously, each paper was assigned an age according to publication date, with 
the minimum possible age being zero years if the paper was published in 2010 and included in 
the Cochrane Library before the date of last search (January 31st, 2010). The most recent papers 
included in this review were published in 2009 and the oldest paper was 14 years old. The age of 
each paper was plotted against the PRISMA score it achieved in order to establish if there was 
any correlation between the two variables. 
 
 
 
Figure 10  Scatter plot of age of paper against PRISMA score 
 
The correlation coefficient was calculated at -0.153, which indicated that there was a weak 
negative linear relationship between age of paper and PRISMA score. The negative value would 
seem to indicate that a younger (i.e. newer) paper was more likely to score higher than an older 
paper. 
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This relationship was significantly different at p=0.040. However, giving the low value of the 
correlation coefficient itself, any improvement in score over time  is likely to be very minor. 
(Table 16). 
 
Table 16 Correlations for PRISMA score vs age of paper 
 PRISMA Score Age of Paper 
PRISMA Score 
            Pearson Correlation 
             Sig. (2-tailed)   
             N            
 
1 
 
181 
 
-0.153 
0.040 
181 
Age of Paper 
            Pearson Correlation 
            Sig. (2-tailed) 
            N 
 
-0.153 
0.040 
181 
 
1 
 
181 
 
 
 
Cochrane and non-Cochrane reviews were also assessed separately in order to determine if one 
of them exhibited greater improvements in reporting quality over time. 
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Figure 11 Scatter plot of age of cochrane review against PRISMA score 
 
In this case the correlation coefficient was -0.324, which again indicated that there was a weak 
negative linear relationship between age of Cochrane paper and PRISMA score.  
This relationship was statistically significant at p=0.019. (Table 17). 
Table 17 Correlations for Cochrane reviews 
 Cochrane Review Score Age of Paper 
Cochrane Review Score 
            Pearson Correlation 
             Sig. (2-tailed)   
             N            
 
1 
 
52 
 
-0.324 
0.019 
52 
Age of Paper 
            Pearson Correlation 
            Sig. (2-tailed) 
            N 
 
-0.324 
0.19 
52 
 
1 
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Figure 12 Scatter plot of age of paper against non-Cochrane PRISMA scores 
The correlation coefficient for the above scatter plot was -0.071. This correlation however was 
not statistically significant, with p=0.422. (Table 18). 
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Table 18 Correlations for Non-Cochrane reviews 
 Non-Coch. Review Score Age of Paper 
Non-Coch. Review Score 
            Pearson Correlation 
             Sig. (2-tailed)   
             N            
 
1 
 
129 
 
-0.071 
0.422 
129 
Age of Paper 
            Pearson Correlation 
            Sig. (2-tailed) 
            N 
 
-0.071 
0.422 
129 
 
1 
 
129 
 
Multiple Linear Regression 
 
A multiple linear regression model was used to determine the contribution of three predictors 
to the final PRISMA score. 
These three predictors are: 
1. The type of review i.e. Cochrane vs non-Cochrane 
2. The speciality the paper is ascribed to 
3. The age of the review 
 
The regression analysis demonstrated that the three predictors contributed to just under 50% 
(0.465) of the variability in the final PRISMA score. (Table 15). The analysis also showed that the 
first two predictors displayed a statistically significant contribution to the final PRISMA score 
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whereas the final predictor, age of paper, did not (p=0.129). The p values for the type of review 
and the speciality of the paper were both p<0.0001. (Table 17). 
 
 
 
Table 19 Regression model summary 
Model R R Square Adjusted R Square Std. Error of the 
Estimate 
1 .689a .474 .465 7.666 
a. Predictors: (Constant), 1,2 and 3 
 
Table 20 ANOVAb 
Model Sum of 
Squares 
Df Mean 
Square 
F Sig. 
1 Regression 
               Residual 
               Total 
9377.500 
10400.567 
19778.066 
3 
177 
180 
3125.833 
58.760 
53.196 p<0.0001 
a. Predictors: (Constant), 1,2 and 3 
b. Dependent Variable: PRISMA score 
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Table 21 Coefficients a 
Model Unstandardised Coefficients 
           B                   Std. Error 
Standardised Coefficients 
Beta 
t Sig. 
1    (Constant) 
Predictor1 
Predictor2 
Predictor3 
104.183 
-15.471 
-1.116 
-0.243 
2.644 
1.268 
0.554 
0.159 
 
0.670 
0.110 
0.084 
39.408 
-12.202 
-2.014 
-1.527 
0.000 
0.000 
0.046 
0.129 
      
a. Dependent Variable: PRISMA score 
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Discussion 
Summary of the main findings 
 
The mean overall score for the systematic reviews, when assessed using the QUOROM checklist, 
was 70.86% (95%CI 69.20%, 70.86%). This means that on average, a systematic review complied 
with approximately 45 out of the 63 items on the checklist.  
The mean overall score for the PRISMA checklist was 74.07% (95%CI 72.53%, 75.61%), indicating 
that each systematic review complied with 47 out of a possible 63 items, on average. Therefore, 
systematic reviews tended to score higher with the PRISMA checklist, by complying with two 
extra items. 
The highest score was 92% which was achieved by three orthodontic Cochrane reviews and one 
Cochrane review in periodontics. The lowest score achieved by any paper was for a non-
Cochrane review in the speciality of preventive dentistry.  
Cochrane reviews made up 29% of the assessed papers. The mean PRISMA score for these 
reviews was 85.19% (95%CI 83.79%, 86.59%), as opposed to 69.59% (95%CI 68.09%, 71.09%) for 
other systematic reviews and meta-analyses. This indicates that on average, Cochrane reviews 
scored 15.6% higher than other reviews and this difference was statistically significant 
(p<0.00001; mean difference 15.60; 95%CI 13.58, 17.62).. 
Amongst the specialities, there were also differences in individual scores. The mean PRISMA 
score was 75.07% (95%CI 72.32%, 77.82%) for orthodontics, 74.91% (95%CI 72.80%, 77.03%) for 
periodontics, 71.50% (95%CI 67.22%, 75.78%) for preventive dentistry and 74.20% (95%CI 
70.33%, 78.07) for endodontics. Therefore, the orthodontic literature scored the highest, when 
compared to the other three specialities however, this difference was not statistically significant 
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(p= 0.85). It could have been related to the fact that orthodontics had the highest number and 
proportion of Cochrane reviews, which were shown to score higher.  
When the Cochrane reviews were assessed within each speciality, it was found that the 
speciality of periodontics scored the highest, with periodontic Cochrane reviews complying with 
87.22% (95%CI 85.16%, 89.28%)of the PRISMA guidelines. Orthodontic Cochrane reviews 
complied with 85.35% ( 95% CI 82.01, 88.70%) of the guidelines, preventive dentistry with 
85.23% (95% CI 83.37%, -87.10%) and endodontics with 83.00% (95% CI 81.15%, 84.85%) of the 
guidelines. Hence, periodontic papers on average obtained a score of 55 out of 63 items,  
orthodontic papers scored 53.7/63, preventive dentistry papers scored 53.6/63 and endodontic 
papers, which scored the lowest, scored on average 52/63. These differences were statistically 
significant ( p value= 0.0196). 
Non-Cochrane reviews were also compared between the specialities and once again 
periodontics scored the highest, with their systematic reviews complying with 72.6% (95% CI 
70.77%, 74.44%) of the PRISMA guidelines. Orthodontics scored the second highest at 69.51% 
(95% CI 67.16%, 71.86%) , followed by endodontics at 68.33% (95% CI 64.26%, 72.41%) and 
preventive dentistry at 65.34% (95% CI 60.76%, 69.93%). In other words, periodontic systematic 
reviews complied with 45/63 items on average, orthodontic papers with 44/63 items, 
endodontic papers with 43/63 items and preventive dentistry, with 41/63 items on average. 
These differences were also statistically significant (p-value= 0.0235). 
The compliance of papers over time was assessed using correlation coefficients, which 
compared the age of each paper with its PRISMA score. The correlation coefficient was -0.153, 
which indicated that there was a weak negative linear relationship between the compliance of 
reviews with the PRISMA guidelines and the year of publication of those reviews. This was 
statistically significant at p=0.040. The correlation coefficients were also calculated for Cochrane 
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reviews and non-Cochrane reviews separately. There was again a weak negative linear 
relationship between the age of a Cochrane review and its PRISMA score, with a correlation 
coefficient of -0.324 and this was statistically significant (p=0.019). . For non-Cochrane reviews 
however, the correlation coefficient was -0.071 which was not statistically significant (p=0.422). 
This indicates that only Cochrane reviews were improving over time.  
A multiple linear regression model was used to determine the contribution of three predictors 
to the final PRISMA score. This showed that the type of review, the speciality of the paper and 
the age of the paper contributed to 50% of the variability of the final PRISMA score. The analysis 
also showed that the first two predictors displayed a statistically significant contribution to the 
final PRISMA score whereas the final predictor, age of paper, did not (p=0.129). The p values for 
the type of review and the speciality of the paper were both p=0.000. 
Interpretation of the main findings 
 
Comparison of checklists 
 
The Bland and Altman test for agreement between clinical measurements was used to compare 
the modified PRISMA and the QUOROM checklists. Another option would have been to calculate 
a correlation coefficient but in this case, the Bland and Altman test was more suitable, because a 
correlation coefficient would not be able to measure bias between two tests, but instead could 
actually show a high level of agreement where two tools obtained consistently different results. 
The Bland and Altman test showed that there was statistically significant bias between the two 
tests, meaning that that the two measurement tools did not agree to a sufficient degree. 
However, visual inspection of the figure (figure 7) indicated that the bias, although significant, 
was for the most part consistent, with each paper obtaining a lower score when assessed using 
the QUOROM checklist and except for a few outliers, most of the QUOROM scores were 
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approximately 3-5% lower than their corresponding PRISMA scores. Accordingly, the two 
checklists could be used interchangeably with adjustments being made to allow for the lower 
scores obtained by the QUOROM checklist. 
 
Main differences between the checklists 
 
The original QUOROM guidelines constituted 13 criteria, which were modified for the purpose 
of this study to give a checklist of 63 items with a maximum possible score of 57. Meanwhile the 
PRISMA guidelines were more detailed and consisted of 27 criteria, which were further divided 
into 63 items to form the checklist constructed for this study. The main reason for breaking 
down the guidelines into a larger number of criteria was to enable a more accurate evaluation 
of each paper. Some of the original criteria were quite detailed with several requirements in 
each, which could potentially increase the likelihood of measurement error, so making sure each 
criterion looked at one specific factor within a paper ensured a more methodological and 
detailed appraisal and potentially allowed areas that were consistently under-reported to be 
identified. 
As mentioned above, the first and main difference between the checklists is the number of 
items in each list. If the same paper was scored with each set of guidelines and the same 
number of points were awarded, the final score as a percentage would still be different as each 
set of points would be divided by a different denominator.  
Another difference between the checklists was the actual criteria themselves. Some criteria in 
the QUOROM guidelines were omitted from the PRISMA statement, while some new criteria 
were introduced into the new statement that had not been included before. Also, the 
distribution of items between the checklists was different. For example, with regards to the 
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abstract, the QUOROM checklist looked at 20 criteria, whereas the PRISMA only looked at 11. 
This resulted in lower QUOROM scores for this section, as there was a higher chance of not 
meeting a criterion. The PRISMA guidelines had new criteria not mentioned in the QUOROM 
statement, such as systematic review registration number, protocol, registration and 
registration information. These generally did not achieve positive scores in most of the papers 
examined, which lowered the PRISMA score in that aspect.  
 
Items that stood out in the QUOROM statement 
 
The wording of several of the QUOROM guidelines did not permit the use of the option of “non-
applicable” on the scoring sheet and hence resulted in a score of “zero” in many of the papers. 
This includes items such as item 20 (inclusion of subgroup analyses), item 44 (utilization of the 
principle measures of effect) and item 45 (method of combining results). If the wording of the 
items had included the phrase “where applicable” at the end, scoring could have potentially 
been more fair, for example where combining results or undergoing subgroup analyses was not 
feasible.  
In the introduction section of the QUOROM checklist, item 15 required the description of the 
characteristics of the RCTs excluded in the results section. Although most papers met the criteria 
to score a “one” in item 14 (characteristic of RCTs included in the results), 63% of papers scored 
a “zero” on item 15. No similar item was found in the PRISMA checklist. Items 28 to 35 looked at 
the inclusion and exclusion criteria. Whereas 89% of the papers scored a “one” for the inclusion 
criteria, only 60% of the papers described the exclusion criteria in sufficient detail to score a 
point. 
Finally, criterion 62, which required the discussion of potential biases in the review process, was 
rarely met, with only 33% of papers adequately discussing this point. 
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Items that stood out in the PRISMA statement 
 
As mentioned previously, the PRISMA guidelines had 12 items related to the title and the 
abstract, compared with 21 items for the QUOROM guidelines. The more succinct division of 
items in the PRISMA statement allowed papers to score higher in the initial items than they did 
in the title and abstract section of the QUOROM guidelines. The only item that scored 
significantly lower in this section was item 12 (systematic review registration number), with 
almost no papers achieving a positive score. 
The development of the PRISMA guidelines 
 
The QUOROM guidelines were published in 19995 but since then a lot has changed. First, there 
has been a great increase in the knowledge about the conduct and reporting of systematic 
reviews. For example, the Cochrane Library’s Methodology Register increased to over 11,000 
entries as of March, 2009.50 Secondly, authors have increasingly used systematic reviews to 
summarise the available evidence from randomised trials. However, despite these advances, the 
quality of reporting of systematic reviews has been below the required standard. This led to a 
panel concluding that the QUOROM statement was flawed and needed to be updated and 
expanded, so they developed the PRISMA statement. 
During the process of data collection in the present study, it was found that the PRISMA 
statement was more easy to follow, as the guidelines were stated more explicitly, while the 
phrasing of some of the QUOROM guidelines was more ambiguous. This made scoring of the 
papers with the PRISMA checklist more straightforward and was preferred by the author. 
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Cochrane versus non-Cochrane reviews 
 
Cochrane reviews scored significantly higher than non-Cochrane reviews and their mean score 
was also found to improve with time, whereas non-Cochrane reviews did not. This is likely to be 
related to the robust editorial process involved in writing a Cochrane review.  
Before any Cochrane review is written, potential reviewers must first propose a title, which is 
negotiated with the Assistant Managing Editor.51 This is followed by submitting a registration 
form. Once the title has been accepted, the authors are then encouraged to attend a workshop 
on protocol development, and will receive a protocol template. The final protocol draft is then 
checked by the Cochrane Collaboration's Information and Management System in RevMan 
format, after careful proof-reading. The protocol itself then undergoes both an internal and 
external refereeing process. It is checked by the Editorial Base, which then sends suggestions for 
improvement back to the authors if required. The revised draft is checked after the 
implementations have been done and then is transferred to the group's editors and external 
referees. They then make comments and once these have been satisfactorily addressed, the 
final protocol is proof read and approved by the Co-ordinating Editor and submitted for 
inclusion in The Cochrane Library to the publisher. 
 
After the protocol has been accepted, the authors receive a review template and proceed with 
preparing the actual review. This template ensures that all reviews are standardised and all-
inclusive. The final review draft is proof-read and sent to the Editorial Base. The Cochrane 
review then undergoes a similar refereeing process to the one conducted on the protocol. The 
final review is then proof read, copy-edited and approved by the Co-ordinating Editor and 
submitted for inclusion in The Cochrane Library to the publisher. There’s also the Cochrane 
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Handbook and style guidelines that set out how each stage should be carried out and there are 
strict quality control guidelines.  
 
Cochrane reviews are also regularly updated, where authors are responsible for searching 
through the literature from the date of the last search to date to identify any recently published 
trials related to their review and to update their review accordingly. This ensures that any new 
trials, that might alter the results of the existing Cochrane review, are included to provide the 
most up-to-date evidence. For these reasons, Cochrane reviews generally of a more superior 
quality to other reviews, which are unlikely to undergo such a thorough process of preparation. 
What do the findings mean? 
 
 The compliance of systematic reviews and meta-analyses with the PRISMA guidelines 
was variable. 
 There were no significant differences in the quality of systematic reviews between the 
four dental specialities. 
 Cochrane reviews scored significantly higher than non-Cochrane reviews. 
 The standard of reporting of Cochrane reviews has improved over time, whereas this is 
not the case with non-Cochrane reviews. 
 
Comparisons with other studies 
 
Due to the recent publication of the PRISMA guidelines, there has only been one study assessing 
the quality of systematic reviews using this checklist48 and this was in the Chinese medicine 
literature. This paper however did not calculate an overall PRISMA score for any of the papers so 
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the results cannot be compared directly. On the other hand, several studies investigated the 
quality of reviews using the QUOROM checklist, as shown in the literature review. 
Systematic reviews of traditional Chinese medicine scored very poorly and did not follow the 
QUOROM guidelines, rendering their results inconclusive.28 This finding is in contrast with this 
study, which showed that although some studies had low scores, others scored very highly, with 
the highest score being 92%. 
Systematic reviews in the Cochrane Neonatal Review Group were shown to have improved after 
the publication of the QUOROM guidelines.29 This is similar to the findings in this study, although 
in this case improvement was assessed over time in general, rather than before and after the 
QUOROM guidelines, per se. No overall score was calculated for the Neonatal Review Group 
Cochrane reviews so this aspect of the results could not be compared. 
Systematic reviews of pneumonia in China were found to score poorly, with the highest score 
being 10 out of 18 items.30 As a percentage this can be expressed as 55.56%, which is 
significantly lower than the 70.86% average found in this study. The difference should be 
interpreted with caution however, as a modified 63-item checklist was used in this study, versus 
the 18-item checklist used in the Chinese study. 
The oncology literature showed that 70% of reviews were not systematic and 21% of the studies 
did not adequately describe their search methods.31 In this study, 83% percent of the 181 papers 
adequately described the search strategy, which is similar to the findings in the oncology 
literature in that aspect. However, whereas they found that most papers were of poor quality, 
this study found that papers scored highly in other items of the QUOROM checklist, which could 
potentially have made up for other low scores.  
A review of meta-analyses dealing with pharmacotherapy of post-traumatic stress disorder32 
concluded that the quality of meta-analyses was acceptable in the PTSD literature, but looking 
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at the actual average score, papers complied with 59.3% of the QUOROM guidelines, which is 
11.56% lower than the results found in this study. 
Systematic reviews and meta-analyses of anxiety disorders scored on average 62%, which is 
8.86% lower than our findings.33 The current study found that the lowest scores were in the 
results section of the papers whereas the highest scores were in the introduction and discussion 
sections of the reviews. Although these aspects were not compared in the present study, a 
preliminary assessment of the scoring spreadsheet shows that the ‘Abstract’ section scored the 
lowest in most papers and the ‘Introduction’ scored the highest. 
 
Health Technology Assessments’ (HTA) compliance with the QUOROM guidelines was variable.34 
Out of 87 papers, 49% of all systematic reviews used a study selection flow diagram. This is 
similar to the systematic reviews looked at in the dental literature, with 45% of papers showing 
a flow diagram in the results section. 
One study, looking at both Cochrane and non-Cochrane reviews in the medical literature, 
demonstrated an increase in score over time, with the score changing from 10.5 out 18 in 2000 
to 13.0 in 2005.35 Again, this is in agreement with the findings of this study, which showed that 
Cochrane reviews improved with time and that the change was statistically significant. When 
analysing the Cochrane reviews in detail, the authors found that they only superseded other 
reviews in the abstract section. However, in the present study, this was not the case. 
One study was identified, which assessed the quality of reporting systematic reviews and meta-
analyses in the orthodontic literature.38  Between 1966 and 2002, 13 papers were identified 
whereas in the present study, 56 papers were identified, because the search was more recent 
and identified papers written until 2009. Papadopoulos and Gkiauris assessed 16 orthodontic 
papers that met their inclusion criteria.39 Each paper was appraised individually according to 
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where the authors thought their deficiencies lay but there was no assessment of the papers 
using specific guidelines and as such, their findings cannot directly be compared to the current 
study. 
 
Limitations of the study 
 
The main limitation of this study is that it was retrospective in nature and hence could 
potentially be subject to bias, due to some reviews not being included in the sample. In order to 
avoid this, the sample was obtained from the Cochrane Library database of systematic reviews. 
The database has been compiled by a combination of electronic searching of several other 
databases and hand searching relevant journals by trained hand searchers, so theoretically, all 
true systematic reviews and meta-analyses should have been identified. Reviews not included in 
the Cochrane Library are unlikely to be systematic, such as literature reviews for example. 
Another limitation could be related to the modified checklists used in this study. The original 
PRISMA and QUOROM checklists consist of lengthy statements detailing different aspects 
required of reviews. In other words, each statement has more than one criterion within it, so 
there would have potentially been some ambiguity during scoring if only have a statement was 
met. In order to overcome this problem and simplify scoring, each statement was subdivided 
into several items, where each item involved only one criterion. This made the process of 
scoring the papers easier and more consistent. The wording of the items in the modified 
checklists remained as close as possible to the original guidelines in order to reduce the 
likelihood of bias. Good intra-examiner and inter-examiner agreement was achieved with the 
developed checklists, so again, bias was unlikely. 
The wording of items was another limitation of the study. For example, items 16 and 17 in the 
PRISMA checklist state: protocol information “if a protocol exists”. In view of this, papers that 
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did not have a protocol scored a “N/A” in these two items, whereas papers with a protocol and 
no elaboration scored a “zero.” As most non-Cochrane reviews with a protocol did not have 
sufficient protocol information, the wording of the items resulted in these papers losing more 
points than papers with no protocol at all. Several other items in the PRISMA checklist were 
worded as “if applicable,” resulting in many “N/As” when a criterion was not met, whereas this 
phrase was rarely used in the QUOROM checklist, resulting in more scores of “zero”. 
 
As the scoring was conducted manually, there was also the element of human error, which 
could have led to bias. One potential for error was examiner fatigue, so in order to reduce this 
risk, only three papers were scored at any one time. Also, the data were entered directly into a 
Microsoft excel data spreadsheet to prevent any error arising from transferring data from a 
sheet of paper to a computer spreadsheet. Entering data into a spreadsheet also reduced the 
likelihood of error when calculating the scores, as this could be done electronically. Again, there 
was good intra-examiner and inter-examiner in the pilot studies, so even if there was any bias, it 
was not significant. 
The original intent of the study was to assess systematic reviews in the orthodontic literature. A 
sample size calculation showed that 165 papers were required to achieve 80% power with a 
0.05 two-sided significance level, which is much greater number than the number of systematic 
reviews in orthodontics. For this reason, three other specialities were included in the study to 
achieve an adequate sample size. Another original intent was to compare papers published 
within three time periods: the five years preceding the QUOROM statement, the five years 
immediately after the statement was published and the last five years. This however proved not 
to be feasible due to the large discrepancies in the sample sizes between the time periods. For 
example, in the orthodontic literature, only three systematic reviews were identified in the 
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Cochrane Library for the first time period, which was not sufficient to make a comparison. For 
this reason, it was decided to test for a correlation between age of paper and PRISMA score, to 
see if there had been any improvement with score over time. Calculating a correlation 
coefficient might not have been the ideal way to test for improvement over time, but with the 
distribution of the papers (most papers were recent and published in the last three years), this 
was probably the most suitable method in this particular case. 
Finally, the publication of the PRISMA guidelines during data collection for the QUOROM 
guidelines necessitated the modification of the study aims and methods. A modified PRISMA 
checklist was compiled and the level of agreement between it and the modified QUOROM 
checklist that was already in use for data collection, was assessed using the Bland and Altman 
test. This showed that although there was a significant difference between the two tools, the 
PRISMA scores were consistently higher than the QUOROM scores by approximately the same 
amount. As the PRISMA guidelines are more recent, they were subsequently used for the 
majority of the study. However, when comparing the results of this study with the results of 
other studies, the data obtained from the QUOROM checklist were used, rather than the 
PRISMA checklist. This is because as of yet, there has only been paper48 looking at the 
compliance of systematic reviews and meta-analyses with the PRISMA guidelines, which was in 
the Chinese literature, so measuring external validity was difficult. 
 
Implications for practice 
 
The results of this study show that the standard of reporting systematic reviews is largely 
variable, with Cochrane reviews scoring significantly higher than non-Cochrane reviews. 
Although Cochrane reviews have been shown to be improving with time, there is still a large 
discrepancy between other systematic reviews published within similar time periods. Future 
 81 
reviews should attempt to follow the PRISMA guidelines more closely in order to improve their 
reporting quality.  
More than 90% of systematic reviews did not include systematic review registration numbers 
and most of non-Cochrane reviews did not include a protocol, both of which are PRISMA 
guideline requirements. These should be included in future reviews and Cochrane updates. 
 
Implications for research 
 
Two modified checklists from the QUOROM and PRISMA checklists have been developed for this 
study which have been shown to be valid and reliable and could be used in further studies. 
Only one other study so far has looked at compliance of systematic reviews with the PRISMA 
guidelines, most likely because the guidelines are relatively new. Future studies can assess the 
compliance of reviews with the PRISMA guidelines, in other parts of the literature. 
This study looked at overall PRISMA scores for papers, but did not specifically look at the 
percentage of papers achieving a score of “1” on specific items. Further research could look at 
the items individually, in order to establish which items scored the highest and which aspects of 
reviews scored the lowest. 
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Conclusions 
 
 The compliance of systematic reviews and meta-analyses with the PRISMA guidelines was 
variable with the mean score being 74.07%. 
 There was a weak negative linear relationship between the compliance of Cochrane reviews 
with the PRISMA guidelines and the year of publication of those reviews. This was 
statistically significant at p=0.019 so the null hypothesis can be rejected. 
 There was a statistically significant difference in the compliance of systematic reviews and 
meta-analyses with the QUOROM statement and the PRISMA statement (p<0.0001). Scoring 
with the PRISMA checklist resulted in consistently higher scores than when utilising the 
QUOROM checklist. Therefore the null hypothesis can be rejected. 
 There was a statistically significant difference in the compliance of Cochrane reviews and 
non-Cochrane systematic reviews with the guidelines of the PRISMA statement (p<0.00001). 
Again, the null hypothesis can be rejected. 
 There was no statistically significant difference between the specialities in the compliance 
with the PRISMA guidelines, so the null hypothesis cannot be rejected at p>0.05. 
 The three independent variables were found to explain approximately 50% of the variability 
of the final PRISMA score. 
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APPENDIX B 
63- item QUOROM Checklist 
Section Item 
No. 
Description 
Title 1 Identification of the report as a meta-analysis or systematic review of RCT’s 
Abstract 2 Use of a structural format 
 3 Description of the clinical question explicitly in the objectives 
 4 Description of the databases used 
 5 Description of other information sources used 
 6 The selection criteria: population described 
 7 The selection criteria: intervention described 
 8 The selection criteria: outcome described 
 9 The selection criteria:study design described 
 10 Description of the methods for validity assessment 
 11 Description of methods for data abstraction 
 12 Description of the study characteristics 
 13 Description of the quantitative data synthesis in sufficient detail to permit replication 
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 14 Description of the characteristics of the RCTs included in the results section   
 15 Description of the characteristics of the RCTs excluded in the results section 
 16 Description of the qualitative findings 
 17 Description of the quantitative findings 
 18 Inclusion of point estimates 
 19 Inclusion of confidence intervals 
 20 Inclusion of subgroup analyses 
 21 Description of the main results in the conclusion 
Introduction 22 Description of the explicit clinical problem 
 23 Description of the biological rationale 
 24 Description of the intervention 
 25 Description of the rationale for review 
Methods 26 Description of the information sources in detail 
 27 Description of any restrictions in the searching process 
 28 Description of the inclusion criteria: defining population   
 29 Description of the inclusion criteria: intervention 
 30 Description of the inclusion criteria: principal outcomes  
 31 Description of the inclusion criteria: study design 
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 32 Description of the exclusion criteria: defining population  
 33 Description of the exclusion criteria: intervention  
 34 Description of the exclusion criteria: principal outcomes  
 35 Description of the exclusion criteria: study design  
 36 Description of the criteria used in validity assessment 
 37 Description of the processes used in validity assessment 
 38 Description of the processes used in data abstraction 
 39 Description of the type of study design 
 40 Description of the participants’ characteristics 
 41 Description of the details of intervention 
 42 Outcome definitions 
 43 Method of assessing clinical heterogeneity 
 44 Utilisation of the principal measures of effect 
 45 Method of combining results: statistical testing and confidence intervals 
 46 Handling of missing data 
 47 How statistical heterogeneity was assessed 
 48 A rationale for any a-priori sensitivity and subgroup analyses 
 49 Assessment of publication bias 
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Results 50 Provision of a meta-analysis profile summarising trial flow 
 51 Provision of descriptive data for each trial: age 
 52 Provision of descriptive data for each trial: sample size 
 53 Provision of descriptive data for each trial: intervention 
 54 Provision of descriptive data for each trial: dose 
 55 Provision of descriptive data for each trial: duration 
 56 Quantitative data synthesis: Reporting agreement on the selection and validity assessment 
 57 Presentation of a simple summary of results 
 58 Presentation of data needed to calculate the effect sizes and confidence intervals 
Discussion 59 Summary of key findings 
 60 Discussion of clinical inferences based on internal and external validity 
 61 Interpretation of the results in light of the totality of available evidence 
 62 Description of potential biases in the review process 
 63 Suggestion of a future research agenda 
 
 
 94 
 
APPENDIX C 
63-item PRISMA checklist with guidance notes 
 
Section  Item Description Comments 
Title 1 Identify the report as a systematic review, meta-analysis, or both.    
Abstract 2 Provision of a structured summary  
 3 Background  
 4 Objectives  
 5 Data sources  
 6 Study eligibility criteria  
 7 Participants  
 8 Interventions  
 9 Study appraisal and synthesis methods  
 10 Results and limitations  
 11 Conclusions and implications of key findings  
 12 Systematic review registration number  
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Introduction 
 
 
  
Rationale 13 Description of the rationale for the review in the context of what 
is already known 
 
Objectives 14 Provision of an explicit statement of questions being 
addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).   
3 out of 5 for PICOS 
Methods    
Protocol and  15 Indication if a review protocol exists  
Registration 16 If a protocol does exist, indication if and where it can be accessed 
 
 
 17 Provision of registration information including registration 
number if a protocol is available 
 
Eligibility 
criteria 
 
18-
26 
Specification of study characteristics: participants   
Specification of study characteristics: interventions 
Specification of study characteristics: comparisons 
Specification of study characteristics: outcomes 
Specification of study characteristics: study design  
Specification of study characteristics: length of follow‐up  
Specification of report characteristics: years considered 
Specification of report characteristics: language   
Specification of report characteristics: publication status 
 
Information 
sources  
27 Description all information sources  
 28 Mention of date last searched  
Search  29 Presentation of full electronic search strategy for at least one 
database, including any limits used, such that it could be repeated  
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Study 
selection  
30 Statement of the process for selecting studies (i.e., screening, 
eligibility, included in systematic reviews 
 
 31 If applicable, statement of the processes for selecting studies 
included in the meta‐analysis 
 
Data 
collection  
32 Description of the method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate 
 
 33 Description of any processes for obtaining and confirming data 
from investigators 
 
Data items  
 
34 Listing and definition of all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made 
At least three of PICOS must be mentioned 
Risk of bias in 
individual 
studies   
35 Description of methods used for assessing risk of bias of 
individual studies (including specification of whether this was 
done at the study or outcome level) 
 
 36 Description of how this information is to be used in any data 
synthesis 
 
Summary 
measures 
37 Statement of the principal summary measures (e.g., risk ratio, 
difference in means) 
 
Synthesis of 
results  
 
38 Description of the methods of handling data and combining 
results of studies, if done, including measures of consistency for 
each meta‐analysis 
 
Risk of bias 
across studies 
39 Specification of any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies) 
 
Additional 
analyses 
40 Description of methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression) if done 
 
Results 
Study 41 Giving numbers of studies screened  
selection 42 Giving numbers of studies assessed for eligibility and included in  
the review with reasons for exclusions at each stage 
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 43 Flow diagram of studies screened and included  
 44 Presentation of characteristics for which data were extracted 
with regards to study size 
 
Study 
characteristics  
 
45 Presentation of characteristics for which data were extracted 
with regards to participants 
 
 46 Presentation of characteristics for which data were extracted 
with regards to interventions 
 
 47 Presentation of characteristics for which data were extracted 
with regards to comparisons 
 
 48 Presentation of characteristics for which data were extracted 
with regards to outcomes 
 
 49 Presentation of characteristics for which data were extracted 
with regards study design 
 
 50 Presentation of characteristics for which data were extracted 
with regards to follow up period 
 
 51 Presentation of characteristics for which data were extracted 
with regards to citations 
 
Risk of bias 
within studies 
52 Presentation of data on risk of bias of each study and, if available, 
any outcome level assessment 
 
Results of 
individual 
studies  
53 For all outcomes considered (benefits or harms), presentation, for 
each study, a simple summary data for each intervention group 
 
 
 54 For all outcomes considered (benefits or harms), presentation, for 
each study, effect estimates and confidence intervals, ideally with 
a forest plot. 
 
Synthesis of 
results  
55 Presentation of results of each meta-analysis done, including 
confidence intervals and measures of consistency 
 
Risk of bias 
across studies 
56 Presentation of results of any assessment of risk of bias across 
studies 
 
 98 
Additional 
analysis  
 
57 Giving the results of additional analyses, if done (e.g., sensitivity 
or subgroup analyses, meta-regression 
 
Discussion    
Summary of 
evidence 
 
58 Summary of the main findings including the strength of evidence 
for each main outcome 
 
 
 59 Consideration of their relevance to key groups (e.g., healthcare 
providers, users, and policy makers)  
 
 
Limitations  
 
60 Discussion of limitations at study and outcome level (e.g., risk of 
bias) 
 
 61 Discussion of limitations at review-level (e.g., incomplete retrieval 
of identified research, reporting bias) 
 
Conclusions 
 
62 Provision of a general interpretation of the results in the context 
of other evidence 
 
 63 Implications for future research    
Funding    
 64 Description of the sources of funding for the systematic review 
and other support (e.g., supply of data); role of funders for the 
systematic review 
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Appendix D 
PRISMA CHECKLIST 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
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PRISMA 2009 Flow Diagram 
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